Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study

WithdrawnOBSERVATIONAL

Timeline

Start Date

October 30, 2017

Primary Completion Date

September 28, 2018

Study Completion Date

September 28, 2018

Conditions

Prostatic Neoplasms, Castration-Resistant

Interventions

DRUG

radium Ra 223 dichloride (Xofigo, BAY88-8223)

Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injections

DRUG

Zytiga

Abiraterone 1000 mg per day orally

DRUG

Xtandi

Enzalutamide 160 mg per day orally